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Background: Vaccination programs often organize subsidies and public relations in order to obtain high uptake
rates and coverage. However, effects of subsidies and public relations have not been studied well in the literature.
In this study, the demand function of pneumococcal vaccination among the elderly in Japan is estimated,
incorporating effects of public relations and subsidy.
Methods: Using a data from a questionnaire survey sent to municipalities, the varying and constant elasticity
models were applied to estimate the demand function. The response variable is the uptake rate. Explanatory
variables are: subsidy supported shot price, operating years of the program, target population size for vaccination,
shot location intensity, income and various public relations tools. The best model is selected by c-AIC, and varying
and constant price elasticities are calculated from estimation results.
Results: The vaccine uptake rate and the shot price have a negative relation. From the results of varying price
elasticity, the demand for vaccination is elastic at municipalities with a shot price higher than 3,708 JPY (35.7 USD).
Effects of public relations on the uptake rate are not found.
Conclusions: It can be suggested that municipalities with a shot price higher than 3,708 JPY (35.7 USD) could
subsidize more and reduce price to increase the demand for vaccination. Effects of public relations are not
confirmed in this study, probably due to measurement errors of variables used for public relations, and studies at
micro level exploring individual’s response to public relations would be required.
Keywords: Demand, Elderly, Vaccination program, Pneumococcal polysaccharide vaccine (PPV), Price elasticity,
Public relations, SubsidyBackground
The administration of 23-valent pneumococcal polysac-
charide vaccine (PPV) has been proven to be effective in
reducing the incidence of invasive pneumococcal disease
caused by Streptococcus pneumoniae (S. pneumoniae)
among the elderly by 50% to 70% [1,2]. It is also effective
in reducing mortality from severe community acquired
pneumonia that requires hospitalization [3,4]. Several
developed countries have implemented national pneu-
mococcal vaccination programs for the elderly in order
to prevent the disease and improve its outcomes [5-8],
although the incidence of the disease varies worldwide
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reproduction in any medium, provided the orSuch programs target high uptake rates and coverages
[10,11], for which subsidies and public relations (PR) are
often organized in order to encourage the elderly to get
vaccinated. However, the effects of subsidies and PR in
publicly funded vaccination program have not been
studied well in the literature. Al-Sukhni et al. (2008)
found that in Canada, physician’s face to face advocacy
inside the consultation room is important for the elderly
to decide for influenza vaccination or pneumococcal
vaccination [12]. Li, Norton, and Dow (2004) examined
the threat-responsiveness hypothesis among the elderly
and their decision to obtain influenza vaccination or
pneumococcal vaccination in the U.S., and found that an
increased associated mortality in the previous year does
not significantly affect the demand for pneumococcal
vaccination but significantly affect the demand for influ-
enza vaccination [13]. Nevertheless, no studies haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Descriptive statistics
n=39
Ratio Mean Min. Max. S.d.
Uptake rate 0.268 0.007 0.991 0.223
Shot price (1,000 JPY) 3.556 0.000 6.500 1.310
Operating years (year) 2.128 1.000 5.000 1.341
Target population
(1,000 persons)
3.625 0.217 44.353 7.139
Location intensity (per km2) 0.474 0.002 9.966 1.599
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elasticity of demand for pneumococcal vaccination.
This lack of knowledge is probably due to the fact that
usually, immunization programs set fixed subsidized
vaccine price for target population, and this makes it
difficult to observe the consumer’s response to price
changes.
In Japan, despite of the fact that pneumonia has been
the fourth leading cause of death among the elderly aged
65 or over since 1975 [14], and that S. pneumoniae is
the most common etiologic agent of community
acquired pneumonia which accounts for 38.7% of such
cases [15], a national pneumococcal vaccination program
is yet to be set. In 2001, however, one town initiated a
pneumococcal vaccination program for the elderly,
under which aged inhabitants were encouraged to re-
ceive a subsidized PPV shot. Subsequently, several muni-
cipalities introduced similar programs, and by 2007,
those amounted to 63 out of all 1,821 municipalities
[16]. These programs set various levels of subsidized
shot price and organized various PR at municipality’s
own discretion, which enable us to observe consumers’
response, that is, the uptake rate, to subsidized price
and PR.
We take advantage of this Japanese context, and aim
to estimate a demand function for pneumococcal vaccin-
ation with price elasticity and effects of various PR tools
on the uptake rate. The results of this study should
deepen our understanding of consumer’s behavior to-
wards preventive health care, and have implications for
health managers in charge of vaccination programs to
organize more effective programs, not only in Japan but
also in other developed countries.
Methods
A questionnaire survey was carried out to all municipal
authorities operating pneumococcal vaccination pro-
grams in 2008. At the time of the survey, 63 municipal-
ities operated programs and the response rate was 100%.
In the survey, following questions were asked: operating
years of the program, definition and size of the target
population, uptake population, price to get one vaccine
shot, number of health facilities providing shots, and PR
tools taken for promoting vaccination. The type of PR
tools included:
To target population
“House-to-house delivery of brochures (PR1)”,
“Distribution of brochures at health facilities (PR2)”,
“Distribution of brochures at public facilities (PR3)”,
“Insert articles in newsletters (PR4)”, “Upload
information to websites (PR5)”, “Hold public events
(PR6)”, “Local cable broadcasting (PR7)”To physicians
“Distribution of brochures to their health facilities
(PR8)”, “Hold information events (PR9)”,
“Communication in regular meetings (PR10)”
To health nurses & care givers
“Distribution of brochures to their health facilities
(PR11)”, “Hold information events (PR12)”,
“Communication in regular meetings (PR13)”
These questions were asked on a Yes/No basis. With
this municipal based data, we assume each municipality
as a market for vaccination and examine the effects of
PR tools implemented by the municipality and subsidy
supported shot price on the vaccine uptake rate.
Descriptive statistics are reported in Table 1. Due to
missing or inadequacy values for data analysis, 39 out of
the 63 municipalities were chosen for the estimation. In-
adequacy values included the price of a shot if it was
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program, or if the municipality had set fixed subsidies to
health care providers and had them decide their own re-
tail shot prices that reflected discretional technical ser-
vice fees. The “Uptake rate” is the uptake population
divided by the target population for vaccination during
the operating years of the program. A municipality with
0.991 in the maximum shows that vaccination program
had run successfully, meaning that 99.1% of the target
population had been vaccinated. The “Shot price” is in-
dividual cost burden for receiving one shot. The 0 in the
minimum means that the individual shot price is fully
covered by the subsidy, and on the other hand, 6.500 in
the maximum implies that the price is not fully covered
and an individual has to pay 6,500 Japanese yen (JPY)
(62.5 USD; 1USD= 104JPY in 2008 annual average) for
vaccination. The “Operating years” is the length of oper-
ating the program. Note the maximum is 5 years, mean-
ing that the data taken is the first 5 years from the
beginning of the vaccine program, therefore there is no
individual who has taken the shot twice. This is because
effectiveness of PPV shot is said to last for 5 years [1]
and revaccination was prohibited in Japan at the time of
the survey. That is to say, the demand for vaccination
would be decided by the shot price, PR, etc., and not by
some sentiment from previous shot experience. The
“Target population” is defined by the age criteria: ≥ 65,
≥ 70, or ≥ 75 years old, depending on the municipality.
The difference of 0.217 in the minimum and 44.353 in
the maximum is not because of age criteria chosen by
municipalities, such as≥ 75 in the minimum and ≥ 65 in
the maximum, but of the population size: one with 0.217
shows a small village and the other with 44.353 shows a
big city. The “Location intensity” is the number of health
facilities providing vaccination per km2 in the municipal-
ity. The “Income” is the average income per capita by
municipality obtained from System of Social and Demo-
graphic Statistics by Statistics Bureau [17]. The demand
function requires a budget constraint information such
as income [18], however, we cannot define the value from
our municipal based questionnaire survey data. And
there was no available income data on the targeted eld-
erly but only of the entire citizen in the municipality. The
“PR1 to 13” are binary or dummy variables which take 1
if the municipality implements the PR tool and take 0
otherwise. 79.5% of the municipalities take PR4, while
only 7.7% take PR9 and PR12. “To target population”,
“To physicians”, “To nurses & care givers” and “Total”
show the number of PR tools implemented by the muni-
cipality during the operating years of the program; PR1
to PR7, PR8 to PR10, PR11 to PR13 and PR1 to PR13, re-
spectively. 3.667 in the mean of “To target population”
describes that municipalities implement on the average
of 3 or 4 PR tools among PR1 to PR7.The “Uptake rate” is the response variable in our de-
mand function, and we have “Shot price” and “Income”
as explanatory variables [18]. As considered to affect the
response variable, “Operating years”, “Target popula-
tion”, “Location intensity” and “PR1 to 13”; “To target
population”, “To physicians”, and “To nurses & care
givers”, and “Total” are also included into the demand
function. If the program has been operating for a long
period of time, it would have become more common
and high uptake rate is expected, in regards to “Operat-
ing years”. The “Target population” is regarded as nature
of works which municipal authorities have to undertake
to promote vaccination. It would be an extreme ex-
ample, but making an effort to increase the uptake rate
for a target population of one person is much easier than
for a target population of 10,000 persons. The “Location
intensity” is regarded as the non-cash price such as
travel or time cost which has been proven to be signifi-
cant in the demand for health care [19] including vac-
cination [20]. Investigating the effects of PR tools on the
uptake rate is the aim of this study, therefore, we include
“PR1 to 13” as dummy variables to examine which PR
tools are effective to increase the uptake rate. In
addition, the number of PR tools implemented by the
municipality is considered as another PR scale, because
it may reflect the intensity of PR within the municipality.
We assume a linier demand function, then the estima-
tion form is expressed as [21]:
Yi ¼ β0 þ β1x1i þ β2x2i þ . . .þ βpxpi
þ εi i ¼ 1; . . . ; nð Þ;
where Y is the response variable “Uptake rate” in this
study, xj j ¼ 1; . . . ; pð Þ are explanatory variables,
βj j ¼ 0; . . . ; pð Þ are the constant and coefficients, ε is the
error term, and n is the sample size. Three models are
estimated: “Shot price”, “Operating years”, “Target popu-
lation”, “Location intensity”, “Income” in all three mod-
els; “Total” is added in model 1; “To target population”,
“To physicians” and “To nurses & care givers” are added
in model 2; and “PR1 to 13” are added in model 3.
In order to examine the effects of explanatory vari-
ables, especially the effects of each PR tool on the “Up-
take rate”, the best model is selected by c-AIC from
model 3 as a full model, with a restriction to keep “Shot
price” and “Income”. This is because “Shot price” and
“Income” are conventional variables in the theory of de-
mand [18]. Then c-AIC is calculated for all possible
regressions with combinations of 16 explanatory vari-
ables. ‘c-AIC’ is the Akaike Information Criterion (AIC)
for small sample data: the smaller the value of c-AIC,
the better the model [22]. Sugiura (1987) suggested that
AIC may perform poorly if there are too many para-
meters in relation to the size of the sample [23]. Our





Model 1 Model 2 Model 3 Model 4 Model 5
Consent 0.557*** 0.618*** 0.641** 0.662*** −1.023***
Shot price
(1,000 JPY)
















































c-AIC −3.608 2.611 49.812 −11.124 113.527
AIC −8.408 −5.246 3.145 −12.942 111.709
Adjust R2 0.235 0.201 0.111 0.274 0.142
Signif codes: 0.01 ‘***’ 0.05’**’ 0.1’*’.
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quite large, in model 3. The best model is created as
model 4.
The price elasticity calculated from the estimation










where x1 is the “Shot price”, β^1 is the estimated coeffi-
cient of the “Shot price”, and Y^ is the expected value of
the “Uptake rate” at x1. From equation (1), model 1,
model 2, model 3, or model 4 is called as the varying
elasticity model since the price elasticity can vary in re-
sponse to changes in x1 and Y^ [24]. Meanwhile, the con-
stant elasticity model takes log(x1) and log(Y), instead of
taking x1 and Y in the varying elasticity model [24]. That
is:
log Yið Þ ¼ β0 þ β1 log x1ið Þ þ β2xpi þ . . . þ βpxpi
þ εi i ¼ 1; . . . ; nð Þ





¼ @ log Yð Þ
@ log x1ð Þ ¼ β^1 ð2Þ
We focus to the best model, which is model 4, and es-
timate the varying and constant price elasticities, using a
command “margins” in the software STATA12 [25]. The
Y^ is calculated with all explanatory variables except x1,
fixed at their means by using a command “atmeans”.
Model 5 is created as the constant elasticity version of
model 4 for reference.
Regarding research ethics, this study is not an experi-
mental research nor carried on humans. It also falls out-
side of the guidelines of health research ethics in Japan.
The data used for this study is openly available, and we
received permission to use this data by all respondents’
municipalities.
Results
Estimation results are listed in Table 2. Model 1, model
2 and model 3 suggest that “Operating years”, “Target
population”, “Location intensity”, “Income”, “Total”, “To
target population”, “To physicians”, “To nurses & care
givers” “PR1 to 13” do not affect the uptake rate, while
“Operating years” in model 1 and “PR5” in model 3 are
significant at 10%. “Shot price” is negatively significant
in all four models, which confirms a negative relation
between the “Shot price” and the “Uptake rate”.
Comparing c-AIC, model 4 has the smallest value and
is regarded as the best among four models. The AIC and
adjusted R2 also imply that model 4 is the best, however,
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−12.942 in model 4, 4.534, is smaller than the corre-
sponding difference in c-AIC, 7.516, which tells us that
c-AIC performs better than AIC in selecting the best
model. The coefficient of the “Shot price” in model 4,
−0.069, explains that the uptake rate is decreased by
6.9% with an increase of the shot price at 1,000 JPY (9.6
USD). Contrary to our expectations, “Operating years”,
“Target population”, and “Location intensity” are not
selected by c-AIC, and “Income” is not found statistically
significant, which implies that these variables have little
effect on the uptake rate. Only “PR2” is selected by c-
AIC but its coefficient sign is negative, however. It is not
clear whether any of these PR tools promotes the in-
crease in uptake rate.
Model 5 is the estimated result of constant elasticity
model. The coefficient of the “log(Shot price)”, −0.148, is
regarded as the constant price elasticity, and it is larger
than −1 and smaller than 0, which implies that the de-
mand for vaccination is inelastic.
Figure 1 describes varying and constant price elastici-
ties calculated from estimation results of model 4 and
model 5, respectively. From (1) and the negative coeffi-
cient value of the “Shot price” in model 4, −0.069, the
varying price elasticity becomes negatively larger as
“Shot price” takes larger positive value. The shot price is
3,708 JPY (35.7 USD) at unit elasticity, i.e., δv = −1.
Therefore, the demand for vaccination is inelastic at the
mean price of 3,556 JPY (34.2 USD), and becomes elastic





















Figure 1 Price elasticity Vs Shot price. Relations between varying
or constant price elasticity and shot price, according to the
estimation results from model 4 or model 5, respectively. Solid lines
show constant and varying price elasticities. Dashed and dotted
lines show the unit elasticity and the elasticity at mean shot price on
the varying price elasticity, respectively.Discussion
We estimate the demand function for pneumococcal
vaccination under subsidy programs incorporating the
shot price, various PR tools and other factors considered
to affect the demand, i.e., the uptake rate. The uptake
rate is found to depend significantly on the shot price.
Therefore, reducing the shot price by subsidy is an ef-
fective implementation to achieve higher coverage. Add-
itionally, we estimated price elasticity of the demand,
which has not been studied well in the literature.
According to the varying price elasticity of demand, the
demand is inelastic, more than – 1, when the shot price
is reduced, supported by larger subsidy. And it is elastic,
less than – 1, when the price is higher with smaller sub-
sidy. Unitary elasticity is estimated at 3,708 JPY (35.7
USD), so municipalities offering higher than 3,708 JPY
(35.7 USD) for a shot can expect substantial gains in up-
take rates by reducing shot prices.
Since only subsidized shot price is available for our
analysis, it is not possible to discuss the direct link be-
tween subsidy and demand. We can, however, give a
probable breakdown of subsidy and shot price. The Na-
tional Health Insurance price list gave 4,835 JPY (46.9
USD) for 23-valent PPV at the time of the survey, al-
though municipalities or vaccination providers might
have purchased at a discounted price for such public
health program that is not covered by the National
Health Insurance reimbursement. And arguably, it can
be assumed that the technical service fee for adminis-
trating one shot levied by physicians is around 5,000 JPY
(48.1 USD). Therefore, the municipality are likely to ex-
pend 10,000 JPY (96.2 USD) to 3,500 JPY (33.7 USD)
per shot as subsidy in order to set the price of a shot at
0 JPY (0 USD) to 6,500 JPY (62.5 USD).
Although we anticipated a result that the demand
increases by implementing more PR tools, their effect-
iveness is not found. Furthermore, any positive effect of
each PR tool on the demand is not observed. However,
we do not think that these results suggest that PR is in-
effective in organizing vaccination programs. On the
contrary, these failures could be attributable to the
measurement errors of variables we used, which are dif-
ficulties inherent in this study. 13 PR tools had been
asked on only a Yes/No basis in the survey because there
was no a priori knowledge about PR practices in this
context. One possible account is a lack of appraisal of
actual contents of each PR tool. It can be assumed that
the contents are divided into two types: information
about arrangement and procedure of the program in-
cluding the shot price; and information about risk and
benefit of vaccination, that is, health education. PR tools
containing price information could cause negative effects
on the uptake rate. And PR tools containing health edu-
cation information might also not work well as it may
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vaccination. It is known that there is a negative attitude
towards vaccination among Japanese health professionals
compared to those of overseas [26]. Their aversion to
vaccination has been firmly rooted by the anti vaccin-
ation campaign in the 1990s in Japan [27], where both
the public [28] and physicians [26] have become to fear
its adverse effects. Therefore, the use of PR in order to
dispel this negative attitude could prompt the demand.
The effects of the operating years of the program and
target population size to the uptake rate were not found,
which could be explained that communicating to the
aged inhabitants may be similar among the municipal-
ities irrespective of time span or size. The location inten-
sity may be failing in measuring the travel cost. The
travel cost to the elderly may not be just direct distance
to health facilities. It depends more on the access
assured by public transportation, or consulting their
home doctor to make their decision in their regular doc-
tor visits, which cannot be caught by number of health
facilities providing a shot per km2.
In addition to the lack of contents and information
regarding PR tools and the travel cost, the number of us-
able observations of only 39 municipalities is small, even
though we used the data set with 100% response rate
and took statistical technique for small samples, i.e., c-
AIC. This may be another reason why anticipated results
were not found in this study.
It is notable that the estimated price elastic demand
for pneumococcal vaccination contrasts with the price
inelastic demand for influenza vaccination among
similar population [29]. These two vaccinations for
the elderly are also found differently in the threat-
responsiveness hypothesis about demand in the U.S.
[13]. Comparative study between the two vaccinations
is awaited to deepen our understanding about this
difference.
This study leaves a room for further study. Particu-
larly, effects of PR on the demand would be of interest
to academics as well as to health managers currently in
practice. Our experience in this study suggests that
rigorous PR measurements for estimating the demand
function across diverse municipal programs is quite diffi-
cult unless any contextual opportunity is offered. Studies
at micro level exploring individual’s response to PR
could be one of the possible approaches to obtain some
evidence.
Conclusions
The elderly’s demand for pneumococcal vaccination
under subsidy programs in Japan is found price-sensi-
tive. Subsidy works, and setting the appropriate level of
price for a shot is important in organizing such pro-
grams. High gains in uptake rates and coverage areexpected by increasing subsidy when the price of a shot
is higher than 3,708 JPY (35.7 USD). The role of PR or
its effectiveness in obtaining high uptake rates and
coverage could not be confirmed in this study.
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